【摘要】 目的观察斯奇康联合化学药物治疗复治及耐多药肺结核的近期及远期效果。方法311例涂阳病人随机分为治疗组及对照组,两组化疗方案相同,治疗组加用斯奇康(卡介菌多糖核酸)。结果复治治疗组痰菌转阴率81.03%,2年复发率6.4%;对照组分别为61.8%、24.2%。耐多药治疗组痰菌转阴率58.3%,2年复发率16.7%;对照组分别为9.4%、60%。经统计学处理皆有显著差异(P<0.05)。结论治疗组疗效明显优于对照组,卡介菌多糖核酸辅助治疗复治及耐多药肺结核可明显提高近期及远期治疗效果。更多还原

【Abstract】 Objective To observe the short -time and forward curative effect of retreated and MDR pulmonary tuberculosis patients treated with BCG vaccine polysaccharide nucleic acid (BCG-PSN). Methods There 311smear- positive cases were divided into trial group and control group at random. All patients were treated with chemotherapy,but the trial group was treated with immunotherapy plus BCG-PSN. The effect was compared between the two groups. Results At the end of treatment,the sputum conversion rates of the retreated pulmonary tuberculosis of the trial group and the control group were 81.03% and 61.8% respectively. As for MDR pulmonary tuberculosis,the rates were 58.3% and 16.7% for the trial group and the control group after a follow-up of 2 years; the recurrent rates of the retreated pulmonary tuberculosis of the trial group and the control group were 6.4% and 24.2% respectively(.all P<0.05 or 0.01). Conclusion The curative effect in the trial group is obvious superior to the control group. As indicated the immunotherapy is more effective in treating the retreated and the MDR pulmonary tuberculosis.更多还原